Journal of Clinical Oncology
Articles in this Issue
Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).
11502 Background: To report results from the open-label alveolar soft part sarcoma (ASPS) cohort of the phase III APROMISS...
Nodal station–mapped recurrence patterns after neoadjuvant immunochemotherapy and R0 esophagectomy for esophageal squamous cell carcinoma.
e16121 Background: Neoadjuvant immunochemotherapy (nICT) followed by R0 esophagectomy is increasingly used for resectable...
Observation on the application effect of biological polysaccharide in radiation-induced oral mucositis of head and neck tumors.
e13596 Background: To explore the effect of 2 different gargles on the prevention and treatment of radioactive oral mucosi...
Association of heparinoids exposure with cytokine release syndrome–related morbidity and mortality in patients receiving CAR-T or BITE therapies.
e14510 Background: Chimeric antigen receptor (CAR)-T and bispecific T-cell engaging (BITE) therapies mediate cytotoxicity...
Efficacy and safety of donafenib combined with PD-1 inhibitors and transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC): A retrospective study.
e16188 Background: Emerging evidence suggests that combining TACE with tyrosine kinase inhibitors (TKIs) and PD-1 inhibito...
Comparative outcomes of first-line atezolizumab plus bevacizumab (A+B) and durvalumab plus tremelimumab (D+T) in hepatocellular carcinoma (HCC).
4163 Background: Standard first-line systemic therapy for hepatocellular carcinoma involves immune checkpoint inhibitors,...
NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC).
5513 Background: NaPi2b is overexpressed in high-grade serous ovarian cancer and non-small cell lung cancer (NSCLC). TUB-0...
Use of multiplex digital profiling of DNA methylation heterogeneity to enable sensitive early detection of non–small cell lung cancer from low-volume liquid biopsies.
10557 Background: Early detection of non–small cell lung cancer (NSCLC) within liquid biopies remains limited by the extre...
A phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma.
TPS9613 Background: The high response rate of neoadjuvant anti-PD-1 has changed the management of locally advanced cutaneo...
Predicting recurrence and survival in hormone receptor–positive (HR+)/HER2-negative (HER2–) early breast cancer (EBC) with machine learning models: Optimization of model complexity.
562 Background: A machine learning model was previously developed to predict distant recurrence (DR) in endocrine therapy–...
Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors.
11005 Background: Remote therapeutic monitoring (RTM) using electronic patient-reported outcomes (ePROs) may help care tea...
Pathologic complete response to neoadjuvant immunochemotherapy in locally advanced head and neck squamous cell carcinoma: Characteristics of 20 responders.
e18011 Background: The use of neoadjuvant immunochemotherapy for locally advanced head and neck squamous cell carcinoma (H...
Lutetium-177-PSMA-617 ( <sup>177</sup> Lu-PSMA-617) in neuroendocrine prostate cancer (NEPC).
e17046 Background: Lutetium-177–PSMA-617 (¹⁷⁷Lu-PSMA-617) improves survival in PSMA-positive metastatic castration-resista...
Integrated NAL-IRI/5-FU/LV, benmelstobart, anlotinib with or without immunoradiotherapy for second-line metastatic pancreatic cancer: A phase II dual-cohort study.
e16374 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an immune cold tumor characterized by stromal an...
Demographics and clinical characteristics of epithelioid leiomyosarcoma: A National Cancer Database analysis.
e23535 Background: Epithelioid leiomyosarcoma is a rare, aggressive variant of uterine leiomyosarcoma, defined by round-to...
High ferroptosis score activity as a predictor of survival and rituximab response in diffuse large B-cell lymphoma.
e19073 Background: Ferroptosis is an iron-dependent form of cell death linked to redox imbalance, tumor immunity, and ther...
Hematologic malignancies to define a distinct high-risk sepsis phenotype among hospitalized cancer patients.
e23245 Background: Sepsis is a leading cause of mortality among hospitalized cancer patients. Although cancer is broadly r...
Quantifying time and financial toxicity of travel for intravesical chemotherapy: Rationale for in-home delivery of bladder cancer treatment.
e13516 Background: Approximately 63,000 adults are diagnosed with non–muscle-invasive bladder cancer (NMIBC) annually in t...
Impact of insurance-related disparities on delay in treatment initiation among colorectal cancer patients in an underserved community teaching hospital.
e23382 Background: Timely treatment after colorectal cancer (CRC) diagnosis is critical, nationally therapy starts within...
A phase II exploratory study of stratified therapy using toripalimab plus GP induction followed by concurrent immunoradiotherapy for locally advanced nasopharyngeal carcinoma.
e18070 Background: Immunotherapy is under extensive investigation for the treatment of locally advanced nasopharyngeal car...
Association of AI-based quantitative B7-H3 evaluation in the tumor microenvironment with molecular subtypes in high-grade serous ovarian carcinoma.
5599 Background: High-grade serous ovarian carcinoma (HGSC) exhibits heterogeneous tumor microenvironments (TME) that corr...
Long-term ctDNA reassessment (LTctDNA) in NSCLC immunotherapy responders.
e20539 Background: Immune checkpoint inhibitors (ICI) with or without chemotherapy are standard frontline therapy for meta...
Progression-free survival as a surrogate endpoint for overall survival in metastatic triple-negative breast cancer: A systematic review and meta-analysis.
1131 Background: Overall survival (OS) remains the gold standard endpoint in metastatic triple negative breast cancer (mTN...
Metal exposure and Ki67 response to neoadjuvant aromatase inhibitor therapy in estrogen receptor-positive (ER+) breast cancer: The NAOMI trial.
e12632 Background: Prior studies suggest that exposure to metals, including arsenic, may be elevated in patients with brea...
Inhaled delivery of KB707, a novel HSV-based immunotherapy, in combination with pembrolizumab in advanced non–small cell lung cancer: A phase 1/2 study.
8564 Background: Though immune checkpoint inhibitors (ICIs) have significantly improved the treatment for lung cancers, re...